Screened 2026-09-09 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
DuPont holds its Markdown at $127.92. Elevated stress, defensive posture warranted, held for 17 days.
As held on the ledger · 2026-09-09
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 17 days
Price at the screen
$127.92
Valuation
55.14 trailing · 16.06 forward price to earnings
Values screen
PASS· score 88.2
Beta
1.09
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
14.80%
Below 33%
Interest-bearing debt is just 14.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.00%
Below 33%
Cash held in interest-bearing accounts and securities is 2.0% of assets, under the one-third limit.
Pass
Receivables
7.53%
Below 49%
Money owed to the company is 7.5% of assets, under the 49% limit.
Pass
Revenue purity
1.43%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades above our $119.15 fair value estimate, weak competitive moat, 4.00% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. The price runs 6.9% above the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +34% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
DuPont trades rich in a cyclical trap
Think of a chemical plant that keeps running even when demand drops off a cliff. DuPont sits in exactly that spot today, priced at a premium while its returns have all but flatlined.
We pass because the shares sit 13 percent above our fair value with a 17.9 times forward multiple, 4 percent revenue growth, zero profit margin and 1 percent ROE. Weak moat plus the cyclical nature of specialty chemicals turns the modest multiple into a warning sign rather than a bargain.
Peak-cycle earnings often look cheap on paper right before volumes and pricing reset lower, and that is the trap here despite the clean ethical screen. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-07-26Markup$135.29+188.8%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 188.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-07-18Markup$46.85+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 22% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 57%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (15 analysts) rates it strong buy, with a mean price target of $57.
2026-07-03Markup$46.85+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$46.85Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
